Hayward Philip A R, Hare David L, Gordon Ian, Buxton Brian F
The Essex Cardiothoracic Centre, Nethermayne, Essex, UK.
Eur J Cardiothorac Surg. 2008 Jul;34(1):113-7. doi: 10.1016/j.ejcts.2008.03.027. Epub 2008 May 1.
In order to determine the best conduit for coronary targets other than the left anterior descending (LAD) artery, long-term clinical outcomes following revascularisation with a radial artery or saphenous vein graft were evaluated as part of the radial artery patency and clinical outcomes (RAPCO) study.
As part of the RAPCO protocol for this prospective, randomised, single-centre trial, patients aged over 70 years undergoing primary CABG were randomly assigned to use of a radial artery (n=113) or saphenous vein (n=112) to revascularise the best non-LAD coronary vessel. Follow-up was annual. Primary clinical end-points were death, myocardial infarction or need for revascularisation. Data were analysed by intention to treat.
The preoperative demographics (age, gender, presence of hypertension or diabetes mellitus) and urgency of surgery did not differ significantly between the two groups. The allocated arterial or venous conduit was utilised as intended in 104/113 and 110/112 patients, respectively. Mean number of grafts was 3.2+/-0.9 and 3.3+/-0.7 in the two groups. During follow-up of mean duration 6.2 years (maximum 10.8 years) there were 16 deaths in each group and 9 vs 13 other events in the radial artery and saphenous vein groups, respectively. These clinical outcomes did not differ significantly (log rank p=0.98 for survival and p=0.52 for event-free survival).
Use of a radial artery or saphenous vein for the second graft during primary CABG does not significantly influence clinical outcome at 6 years. Mean 5-year angiographic patency data are awaited, but from the patient's perspective the likelihood of a satisfactory long-term result is equivalent, whichever conduit is used.
为了确定除左前降支(LAD)动脉外用于冠状动脉靶点的最佳血管 conduit,作为桡动脉通畅性和临床结果(RAPCO)研究的一部分,评估了使用桡动脉或大隐静脉移植进行血运重建后的长期临床结果。
作为这项前瞻性、随机、单中心试验的 RAPCO 方案的一部分,年龄超过 70 岁接受初次冠状动脉旁路移植术(CABG)的患者被随机分配使用桡动脉(n = 113)或大隐静脉(n = 112)对最佳非 LAD 冠状动脉血管进行血运重建。随访为每年一次。主要临床终点为死亡、心肌梗死或血运重建需求。数据按意向性分析。
两组术前人口统计学特征(年龄、性别、高血压或糖尿病的存在情况)和手术紧迫性无显著差异。分别有 104/113 和 110/112 例患者按计划使用了分配的动脉或静脉 conduit。两组的平均移植血管数分别为 3.2±0.9 和 3.3±0.7。在平均 6.2 年(最长 10.8 年)的随访期间,每组各有 16 例死亡,桡动脉组和大隐静脉组分别有 9 例和 13 例其他事件。这些临床结果无显著差异(生存的对数秩检验 p = 0.98,无事件生存的 p = 0.52)。
在初次 CABG 中使用桡动脉或大隐静脉作为第二根移植血管在 6 年时对临床结果无显著影响。平均 5 年的血管造影通畅数据有待获取,但从患者角度看,无论使用哪种 conduit,获得满意长期结果的可能性是相当的。